vadimezan has been researched along with 2-bromopalmitate in 1 studies
Studies (vadimezan) | Trials (vadimezan) | Recent Studies (post-2010) (vadimezan) | Studies (2-bromopalmitate) | Trials (2-bromopalmitate) | Recent Studies (post-2010) (2-bromopalmitate) |
---|---|---|---|---|---|
272 | 16 | 101 | 139 | 0 | 53 |
Protein | Taxonomy | vadimezan (IC50) | 2-bromopalmitate (IC50) |
---|---|---|---|
Palmitoyltransferase ZDHHC2 | Homo sapiens (human) | 2.02 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Akiba, T; Arai, H; Barber, GN; Kobayashi, T; Konno, H; Mukai, K; Taguchi, T; Uemura, T; Waguri, S | 1 |
1 other study(ies) available for vadimezan and 2-bromopalmitate
Article | Year |
---|---|
Activation of STING requires palmitoylation at the Golgi.
Topics: Animals; Chlorocebus aethiops; COS Cells; Embryo, Mammalian; Endoplasmic Reticulum; Fibroblasts; Gene Expression Regulation; Golgi Apparatus; HEK293 Cells; Herpesvirus 1, Human; Humans; Immunity, Innate; Interferon Type I; Lipoylation; Membrane Proteins; Mice; Mutation; Palmitates; Primary Cell Culture; Protein Serine-Threonine Kinases; Protein Transport; Xanthones | 2016 |